Sentia is poised to be the world leader in the development of novel peptide therapeutics to manage and cure stress-related diseases by developing drugs called astressins that block the action of corticotropin releasing factor (CRF) and urocortins, the main mediators of the body’s response to stress. Astressins are designed to re-establish normal biological harmony with high efficacy and sustained effects.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.